---
title: "3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2025"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/281061806.md"
description: "3SBio Inc. reported earnings results for the full year ended December 31, 2025. For the full year, the company reported sales was CNY 17,695.75 million compared to CNY 9,107.98 million a year ago. Net income was CNY 8,482.16 million compared to CNY 2,090.32 million a year ago.Basic earnings per share from continuing operations was CNY 3.51 compared to CNY 0.86 a year ago. Diluted earnings per share from continuing operations was CNY 3.43 compared to CNY 0.85 a year ago."
datetime: "2026-03-30T17:38:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/281061806.md)
  - [en](https://longbridge.com/en/news/281061806.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/281061806.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/281061806.md) | [English](https://longbridge.com/en/news/281061806.md)


# 3SBio Inc. Reports Earnings Results for the Full Year Ended December 31, 2025

3SBio Inc. reported earnings results for the full year ended December 31, 2025. For the full year, the company reported sales was CNY 17,695.75 million compared to CNY 9,107.98 million a year ago. Net income was CNY 8,482.16 million compared to CNY 2,090.32 million a year ago.

Basic earnings per share from continuing operations was CNY 3.51 compared to CNY 0.86 a year ago. Diluted earnings per share from continuing operations was CNY 3.43 compared to CNY 0.85 a year ago.

### 相關股票

- [ICBCCS SSE STAR Biology and Medicine ETF (588860.CN)](https://longbridge.com/zh-HK/quote/588860.CN.md)
- [Tianhong CNI BIOMEDICINE ETF (159859.CN)](https://longbridge.com/zh-HK/quote/159859.CN.md)
- [Bosera Hang Seng Health Care ETF(QDII) (513060.CN)](https://longbridge.com/zh-HK/quote/513060.CN.md)
- [E Fund CSI Biotechnology Theme ETF (159837.CN)](https://longbridge.com/zh-HK/quote/159837.CN.md)
- [3SBIO (01530.HK)](https://longbridge.com/zh-HK/quote/01530.HK.md)
- [ChinaAMC CSI Biotechnology Theme ETF (516500.CN)](https://longbridge.com/zh-HK/quote/516500.CN.md)
- [E Fund Hang Seng SCHK Innovative Drug ETF (159316.CN)](https://longbridge.com/zh-HK/quote/159316.CN.md)
- [Bosera Hang Seng SCHK Innovative Drug Select ETF (520690.CN)](https://longbridge.com/zh-HK/quote/520690.CN.md)
- [China Merchants CSI Biotechnology Theme ETF (159849.CN)](https://longbridge.com/zh-HK/quote/159849.CN.md)
- [ChinaAMC SSE Health Care ETF Initiating Fund (510660.CN)](https://longbridge.com/zh-HK/quote/510660.CN.md)
- [ChinaAMC SSE STAR Biology and Medicine ETF (588130.CN)](https://longbridge.com/zh-HK/quote/588130.CN.md)
- [ChinaAMC Hang Seng Biotechnology Technology ETF(QDII) (159892.CN)](https://longbridge.com/zh-HK/quote/159892.CN.md)
- [Huaan Hang Seng Biotech ETF (159102.CN)](https://longbridge.com/zh-HK/quote/159102.CN.md)
- [Penghua SSE STAR Biology and Medicine ETF (588250.CN)](https://longbridge.com/zh-HK/quote/588250.CN.md)
- [Guotai CSI Bio-medicine ETF (512290.CN)](https://longbridge.com/zh-HK/quote/512290.CN.md)
- [Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF (159506.CN)](https://longbridge.com/zh-HK/quote/159506.CN.md)
- [China Southern Hang Seng Biotech ETF(QDII) (159615.CN)](https://longbridge.com/zh-HK/quote/159615.CN.md)
- [Ping An CSI Medicine and Medical Device Innovation ETF (516820.CN)](https://longbridge.com/zh-HK/quote/516820.CN.md)
- [Yinhua CSI Innovative Drugs Industry ETF (159992.CN)](https://longbridge.com/zh-HK/quote/159992.CN.md)
- [E Fund CSI 300 Health Care ETF (512010.CN)](https://longbridge.com/zh-HK/quote/512010.CN.md)
- [Minsheng Royal CSI Biotechnology Theme ETF (516930.CN)](https://longbridge.com/zh-HK/quote/516930.CN.md)
- [Hwabao WP Hang Seng SCHK Innovative Drug Select ETF (520880.CN)](https://longbridge.com/zh-HK/quote/520880.CN.md)
- [GF CSI HK Innovative Drugs Industry ETF(QDII) (513120.CN)](https://longbridge.com/zh-HK/quote/513120.CN.md)
- [Founder Fubon CSI Medicine and Medical Device Innovation ETF (560600.CN)](https://longbridge.com/zh-HK/quote/560600.CN.md)

## 相關資訊與研究

- [3SBio Nearly Doubles Revenue and Quadruples Profit in 2025, Keeps Dividend Steady](https://longbridge.com/zh-HK/news/281054154.md)
- [Sunho Biologics Flags Audit Delays as Auditor Seeks More Documentation](https://longbridge.com/zh-HK/news/280992698.md)
- [Akeso FY revenue RMB 3,056.3 million](https://longbridge.com/zh-HK/news/280664190.md)
- [Junshi Biosciences Chairman Completes RMB100 Million Shareholding Increase](https://longbridge.com/zh-HK/news/281231901.md)
- [ImmuneOnco Doses First Patient in Phase III Trial of CD47/CD20 Bispecific for Lymphoma](https://longbridge.com/zh-HK/news/281068292.md)